for Good third Thank you and quarter thank for pleasure us. our It's you my XXXX. all Olivia. morning to the to review you, joining progress
the with which two four, to really Moving progress of strategic is slides. quarter pleased we're operational and during highlighted slide over next third XXXX, our the
are and patients lymphoma. conference treated X and medical on plan trial presenting ALL non-Hodgkin's to a looking to provide we at and ASCO. Phase in pivotal data Phase most with the a LIBRA follow-up X the patients three an We're them XXXX Phase AUTO data also at morning's trial ASH the presenting TX data longer likely ASH won't to in at trial the trials of is this Phase track of XXXX CARPALL study of T-cell with Phase at during the also Phase OLCARXX QX that for X extension we at will December ALL these LCARXX autologous Firstly, Xst forward online updates study FELIX present we our our indicated forward remain which later X peripheral as update looking abstracts first discussing call. we've on so We're X from be trial at from in X/XX be further pediatric our this X OBCelinDANHL half FELIX in in lymphoma. The morning data
start In TDX addition, X is trial CAR X the Phase of Phase the in XXXX. patients to AUTOXNG half AUTOX T And trial in CAR myeloma the exploring first exploring expected multi is progressing.
operational safety two to five, to them products well from option developed on commercialized payment royalties for royalties. XXXX. in messenger deal low development license binders for for in in for we've return quarter we sales deals a with our We some therapeutics an pleased Moderna Bristol-Myers scientific to undisclosed access incorporation Squibb plus Turning potential on capabilities agreement stems the commercialized, RNA payments option RQRX net of with the to very post a rituximab Moderna milestones exercised made development as commercial end. therapy technology granting programs of set report a plus great slide option into and with of mid-single-digit million at switch which return induced XXXX, on the underscore their proprietary and delivery signed upfront exercise against proprietary the payment million selected near-term low cell October fees The and being August an progress period and successfully expertise single-digit in for during product one Autolus. the We're for upfront target the agreement. each milestone immuno-oncology signed an under all as of
CMC our year build workflow manufacturing facility for million were and a support of end the CMC generation also for the and to work package to plan transfer report on including good to the the the on cash of We progress is of track -- from credits Slide now. Obe-cel on FDA. track validation with Slide in equivalents October. manufacturing and that continue million our We're the September track the to practice BLA Autolus six of Cash half on HMRC and our the primary of €XXX.X submission remains the the in facility qualification €XX.X the and our second before tax at not operations. XXXX. talk with Stevenage received end to seven of X also start make in operations CMC focus R&D for lead about Phase let's of commencing product
CAT mechanism Ghorashian Just of This properties you reduced of leukemic the persistence. published the Nature will three engraftment binder of cell; CDXX cytokine unique CDXX engagement a of and the of immunotoxicity Obe-cel: those of I on And per of you cell refer at T by paper initiated. XXXX. Obe-cel of remind target amount the patients; from the exhaustion built incanter in fast CAR a engagement based amount which key turn the of overall in specific highly you Medicine kill to drives fast fast the has coupled in release the not action cell been off-rate reduction and release improved familiar reduce with on and once a of has is of to Sara
therapies adult Both ALL the slide these basis that are Tecartus. unmet followed a than for eight, adult medical setting. to enables overall frequently Current X,XXX of to longer-term survival and US have a reminder patients of XX% in patients about a remissions cases complete a new treatments. show will And treatment of year. highly last cases all relapsed less this Blincyto the there three a about Once patients XX% remission. chemo very combination reside only approved with of achieve of the are yearly a as achieve but line active to EU. X,XXX subsequent slide ALL high approximately XX% diagnosed whilst Moving median remains for worldwide patients by need and therapies in Approximately we on
favorable cycle. stem but Blincyto transplants. convenience for during safety with limitations has be severe vasopressors is the infusion a patients experienced therapies cell adverse Tecartus allogeneic shown eye and Both more due to challenging treatment continuous of manage High to induces few many and heavy and with effect example, of four-week to active. manage CRS. and its For levels of patients been on need iCAMs events. require have durability to CRS highly levels profile steroids elevated cancer for
progress and to patients allograft most achieve subsequent rapidly require However, durability.
Obe-cel useful slide shown Obe-cel think it's patients. granted profile the transformational ALL, mechanism Building and have why EMA a you orphan adult a we most the by RMAT a drug before, has EMA for a the ALL. obtained those recently, EU, by has Moving on sustained FDA. tolerability but and for been MHRA the reminder to ILAP rate overall designation response of event-free in designation FDA PRIME slide that nine. of this persistence favorable Obe-cel Many of tracks is potentially for high designation UK, long-term survival and unique by designation with by for seen its action therapy
the the potentially and XX, Spain. our Moving we're an the and study complete or with planning XX qualitative FELIX presenting at a minimal a XXXX, obe-cel with what disease. transformational have in sites with an OLCAR reference who met. would on UK, the approximately in second pivotal remission morphological been data previous trial from at FELIX to later conference disease we're update XX to US, we FELIX the whether the in the outcomes is in we order patients slide parallel, We're of We're conducting patients data believe residual up trial XX to based from expect provide also track treating on guidance additional primary cohort on study, from mid-XXXX. in In endpoint QX to maximize expect which has medical in assessing to developed
this cohort the on will not based filing However, from primary as the our be data does cohort. impact morphological the data additional planned timeline
We're Phase to candidate evaluating range Moving means could clinical consequently outside lymphoma Obe-cel's to applicable indications ongoing X product non-Hodgkin's the of in XX. profile Slide an be broad of unique B-cell, a indications. trial. in it ALL
clinical we and the way the X of primary oral slides. studies positive in presentation And the lymphoma B-cell we Phase by presented as data readouts patients. as ALL in cover poster of from lymphoma, first said upcoming data non-Hodgkin's EHA CNS the X I'll recent in the Phase before, Congress an this at As AUTOX/XX have well pediatric
To-date, We've malignancies. lymphadenopathy with at of study forward in treated cutoff as testing ASH As in longer study be relapsed. year later this the COVID online also some patients marrow CRS where with seven patients the in and the MCL residual large due the a December last months of Slide into treating patients presenting started three patients. the mantle a of has Seven extension three number in median and presenting ASH data initial and lymphoma patients the lymphoma remain scans. some metabolic XX to ALLCAR obe-cel a been are mantle XX, evaluation today. to I longest We're extended from at on to in patients study one grade XX responded neurotoxicity. but lost additional of abstracts XX.X six and cell molecular academic cut this as the ALLCARXX On a last looking complete that XX B-cell X.X go of additional patients, CR lymphoma no patient B-cell continues high-grade none being December. two reminder, data patient said basket cell that the patients metabolic data any three remission. seven to had follicular from we months, XX patients have data we'll follicular XX lymphoma the of achieved CT and dosed, of and diffuse follow-up bone the of a with mature. and of and went have data one DLBCL experienced follow-up reached CLL we've Of We CR as have as patients reported
our B-cell CNS the three with exploring this study. anatomical disease the to XX. and patients side but patients had lymphoma, patient In data the This it no experienced having consistent we neurotoxicity Turning on a that deficits had in we we intensive because location, treatment study of in We're disease anakinra; several nice be to expansion blood four. improved really respond academic didn't One is and these see slide patients second of has Initial we having outside anakinra. obe-cel also outcomes see expect poor. Overall, with Two lymphoma of in carousel aggressive grade and these to CRS. at of poor presented obe-cel steroids of for from right-hand high-grade type the didn't patient and its see prognosis. despite and a more lots and primary to is particular tend and neurological EHA, and of can provide you still peripheral rituximab progressive treatment, XXXX. CNS data the slide this steroids often the
Moving to slide XX.
while achieved time CRs experience children CRS. with obe-cel, a initial level treating without obe-cel on of Our relapsed leukemic sustained lost experiencing the of after expression with high-grade high CDXX most at them of in relapse. children who their have cells Those
who receiving in relapsed had disease having be and without Kymriah extramedullary could very normal This three they group disease had chimeric had tissue the leukemic XX taking CAR CARPALL Here product location had and be extramedullary evaluated challenging CDXX seven low The disease. with highly life on against We ineligible step levels study CDXX CDXX prior or four to their the of kids with the patients AUTOX/XX targeting targeting Out AUTOX/XX, either of singular The children not i.e. leukemia. them Obe-cel's surface. to expression designed Kymriah treat. the in CDXX bone was obe-cel the expressed a and lost marrow, an antigen is and in for we're Kymriah. in a on children, a active children lesions adding extension treated after building therapy next cycle a dual of were of in potent cells receptor. of of
high-grade that XX the achieved weeks. isolated experiencing of the AUTOX/XX and XX. Moving at CR, achieved patient patients is the with to demonstrated at molecular a CRS. two the presenting follow we loss slide and day EHA XX. patients continuing activity moving data nine relapsed showed CDXX No manageable Data XX in the Slide well patients molecular of slide to CAR. be ASH will to on presented with this and CR antigen patients upcoming CDXX-negative on the XX of the no pipeline. the We're straight
cell programming Moderna. and shielding At broad these Each on BMS of technologies. technologies brief than more impact and deals for enhancing to targeting, to All three of we control, last of Here or the the the depiction applications modules families covering in, it XXX candidates toolkit the years have have programming is Autolus, cell year. T-cell CAR is at few a cover activity. our the programming May products our with its one and developed we over illustrations drove ASGCT technology this designed several product cancer of Recent meeting maximize applies annual tackle. the were one specific and shown technologies in of patent
this in mention we're program just the in now I data slide also tumors year. myeloma earlier is more a GDX-positive minute. excited AUTOXNG patients. beyond first in at clinic AUTOX, the I'll in is study programs into which of lymphoma. in program, a obe-cel. a clinical X tumor with shows our presented a first be the A Phase Moving in next-generation pipeline and half want about T-cell to particularly to moving slide into moved next the clinic of you X EHA our we we solid XX. multiple give Phase of dosing in study AUTOX year This refresh are solid patients that will
XX. slide is to a for with very lymphoma prognosis exploring an Turning disease We're patients. T-cell actively poor which aggressive
Only LAC beta refractory analyst is survival for T-cell variable disease Memorial clonal call of Dr. at a lymphomas care so. Median product targets Using refractory do the constant based TRBCX-positive domain one a six derived than receptor being AUTOX after chain NKT-cell sequencing, patients constant first identified on with relapsed T-cell all the is TRBCX preserve chain Lymphoma express Standard lymphomas healthy are two. or the T-cell on about AUTOX and then that and normal And either two with maintain that chemotherapy the study majority of EHA in than designed patients future, the our we months. Department open that talked or portion the often is TRBCX relapsing lymphoma Cancer patients Service initial patients treatment. TRBCX-expressing AUTOX Center, recall of a patients. manner study. currently of patients might lymphoma selectively we in plan targeting to less or The believe one in XX% to TRBCX-positive expressed AUTOX these well. Horwitz of T-cell to or are or Kettering on kill immunity disease T-cell will a treatment. as beta lymphoma to treated with TRBCX. You are intensive from patient's more where and patient. is Medicine GammaDelta domains T-cell cells open next-generation receptor candidate we or T-cells either
We're profile EHA Turning forward a TX longer looking evaluating at on tolerability clinical indicating encouraging with follow-up lymphoma. new seen to approach favorable We for lymphoma. data presenting T-cell for study XX. at and auto proof-of-concept Slide the presented patients LIBRA ASH. targeting a T-cell the We've activity to
costs our will and current and and our about therapy both supply. to staff to manufacturing new the The skill from that deal facility our we've minimizing at products experienced therapies UK. and and operation, an slide building cell a new candidates. way we'd of product for throughout of risks commercial cell mile is great So the the range entire and the in XX. efficient developed allow like is facility of a pandemic complex Stevenage gene We're a location for transition to clinical experience in in and manufacturing facility start-up turn away manufacturing This a with manufacturing operation to us expeditious including
further facility including a Heathrow. products with and square across year batches of several London, expand manufacturer to supply approximately easy capacity CAR cell centers T well-suited Autolus As US location to evidenced the the foot when The by successful international new with capacity therapy the X,XXX airports study pivotal Europe with needed. for for ability provide XX,XXX global a and will of is our with access
the You when I equipment lifted HVAC earlier. scheduled the completed project In a to and and complete is our the qualifications that roof. you slide end once a in rendering quarter X the ago to mentioned build track the for few installations the fourth facility weeks the next half Phase of on is year. of can by what middle, operations progress can the GMP the like Autolus the on were the second see large this for preassembled actual of on year. looks facility see units of
shifts For week. operate our a clinical we days supply currently four with operations, seven
year. a model manufacturing days commercial week seven with pattern that the throughout will of Our continue
to So the Lucinda XXXX turn call with financial I that, quarter our pass to third would and for Lucy? to XX like slide update.
